Andres Ortega

411 total citations
10 papers, 202 citations indexed

About

Andres Ortega is a scholar working on Organic Chemistry, Physiology and Molecular Biology. According to data from OpenAlex, Andres Ortega has authored 10 papers receiving a total of 202 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Organic Chemistry, 5 papers in Physiology and 4 papers in Molecular Biology. Recurrent topics in Andres Ortega's work include Carbohydrate Chemistry and Synthesis (5 papers), Lysosomal Storage Disorders Research (5 papers) and Glycosylation and Glycoproteins Research (2 papers). Andres Ortega is often cited by papers focused on Carbohydrate Chemistry and Synthesis (5 papers), Lysosomal Storage Disorders Research (5 papers) and Glycosylation and Glycoproteins Research (2 papers). Andres Ortega collaborates with scholars based in United States, Canada and Lebanon. Andres Ortega's co-authors include Heping Zhou, Manisha Balwani, Pramod K. Mistry, Seymour Packman, Suma P. Shankar, Michel Peterschmitt, Charles desBordes, Sarit Assouline, Marwan Ghosn and Ryan Chung and has published in prestigious journals such as Blood, Cancer Research and American Journal of Hematology.

In The Last Decade

Andres Ortega

10 papers receiving 198 citations

Peers

Andres Ortega

PHYSI

EPIDE

Jeanine Utz United States

Andrea M. Atherton United States

Xiaolong Sui China

Yuanhong Sun United States

Susanne Theiß Germany

Lilu Guo United States

Ana Carolina Brusius‐Facchin Brazil

Zhiwei Luo China

Михаил Николаев Russia

Alex Colville United States

Jeanine Utz United States

Andres Ortega

128 ×1.1

PHYSI

81 ×1.0

9 ×0.2

40 ×0.8

EPIDE

39 ×0.8

Citations per year, relative to Andres Ortega Andres Ortega (= 1×) peers Jeanine Utz

Countries citing papers authored by Andres Ortega

Since Specialization

Citations

This map shows the geographic impact of Andres Ortega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andres Ortega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andres Ortega more than expected).

Fields of papers citing papers by Andres Ortega

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andres Ortega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andres Ortega. The network helps show where Andres Ortega may publish in the future.

Co-authorship network of co-authors of Andres Ortega

This figure shows the co-authorship network connecting the top 25 collaborators of Andres Ortega. A scholar is included among the top collaborators of Andres Ortega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andres Ortega. Andres Ortega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Mistry, Pramod K., Elena Lukina, Hadhami Ben Turkia, et al.. (2021). Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. American Journal of Hematology. 96(9). 1156–1165. 31 indexed citations

Mistry, Pramod K., Elena Lukina, Hadhami Ben Turkia, et al.. (2017). Long-term results of ENGAGE: a phase 3, randomized, double‑blind, placebo-controlled, multi‑center study investigating the efficacy and safety of eliglustat in adults with type 1 Gaucher disease. Molecular Genetics and Metabolism. 120(1-2). S97–S98. 4 indexed citations

Mistry, Pramod K., Elena Lukina, Hadhami Ben Turkia, et al.. (2017). Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial. American Journal of Hematology. 92(11). 1170–1176. 73 indexed citations

Mistry, Pramod K., Dominick Amato, Majed Dasouki, et al.. (2015). ENGAGE — A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: Results after 18months. Molecular Genetics and Metabolism. 114(2). S81–S82. 8 indexed citations

Amato, Dominick, Majed Dasouki, Seymour Packman, et al.. (2014). Engage - a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Eliglustat in Adults with Gaucher Disease Type 1: Results after 18 Months. Blood. 124(21). 2732–2732. 4 indexed citations

Torres‐Unda, Jon, et al.. (2013). Effects of Vibration Therapy on Hormone Response and Stress in Severely Disabled Patients: A Double-Blind Randomized Placebo-Controlled Clinical Trial. Rehabilitation Nursing. 40(3). 166–178. 3 indexed citations

Lea, Michael A., et al.. (2011). Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin.. PubMed. 31(2). 421–6. 38 indexed citations

Lea, Michael A., et al.. (2011). Abstract 4069: 2-deoxyglucose and compound C reversed acidification but enhanced growth inhibition in colon cancer cells treated with metformin and phenformin. Cancer Research. 71(8_Supplement). 4069–4069. 1 indexed citations

Ortega, Andres, et al.. (2010). Postnatal development of lipopolysaccharide-induced inflammatory response in the brain. Inflammation Research. 60(2). 175–185. 23 indexed citations

10.

Surriga, Oliver, et al.. (2009). Altered hepatic inflammatory response in the offspring following prenatal LPS exposure. Immunology Letters. 123(1). 88–95. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact